Sanara MedTech Inc. · NASDAQ:SMTI
Sanara MedTech — Q4 2022 Earnings Presentation
8 slides from Sanara MedTech's earnings presentation, Feb 20, 2023
Slide 1: Q4 and Full-Year 2022 Earnings and Business Update Call
Q4 and Full-Year 2022 Earnings and Business Update Call
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Overview: Commentary on Q4 and Full-Year 2022
Overview Commentary on Q4 and Full-Year 2022 • Financial Update • Highest net revenue year ($45.8 million) and quarter ($15.3 million) in the Company’s history for the business as well as for the historical business before taking into account the $6.0 million in sales resulting from the Scendia acqu
Slide 4: Product Sales
Product Sales Sales Overview • 39 field sales representatives as of December 31, 2022 • CellerateRX® Surgical sold in over 700 hospitals/ASCs across 29 states(1) in the TTM • CellerateRX® Surgical approved to be sold in more than 1,700 hospitals/ASCs as of December 31, 2022 • Total estimated availab
Slide 5: Sanara MedTech: A Comprehensive Solution for Wound and Skin Care
Sanara MedTech A Comprehensive Solution for Wound and Skin Care Sanara MedTech’s Goals: Data analytics will be used to build and refine clinical practice pathways. • Bring a proven efficacious wound and skin care solution to patients in the lowest Improved Wound and Dermatology Outcomes and cost set
Slide 6: 2022 Financial Highlights
2022 Financial Highlights Overview • Revenue • For the year, Sanara generated net revenues of $45.8 million compared to net revenues of $24.1 million for the year ended December 31, 2021, representing a 90% increase from the prior year period. • 2022 net revenues included $6.0 million of Scendia sal
Slide 7: 2022 Financial Highlights (Continued)
2022 Financial Highlights (Continued) Overview (Continued) • Other Expense • Other expense for the year ended December 31, 2022 was $1.7 million compared to $0.6 million for the year ended December 31, 2021. • Higher other expense in 2022 was primarily due to a $1.0 million loss recognized due to th
Slide 8: Questions
Questions Evidence Based Healing